Hello, this is Daily Stock, reading the pulse of the market and exploring sustainable investment strategies.
[Image: /stdaily/uploads/202609/gen_6aa8ed1cd90523.78840653.png]
Executive Summary
Celltrion's "Zymfentra," the world's only subcutaneous (SC) formulation of infliximab, has completed formulary listings across the top three U.S. Pharmacy Benefit Managers (PBMs), securing over 90% reimbursement coverage.
In the first half of 2026, standalone sales of Zymfentra reached KRW 99.5 billion, surging 176.4% year-over-year. Combined global sales with Remsima SC hit KRW 456.2 billion, significantly raising the likelihood of the franchise achieving annual blockbuster status exceeding KRW 1 trillion.
As the KOSPI experiences short-term volatility around the 6,627.26 level and the Fear & Greed Index points to 25 (Fear), Celltrion’s fundamental defensive strength and valuation appeal are coming into focus, underpinned by export-driven, high-margin novel drug performance.
Current Market Situation
On September 15, 2026, Celltrion (068270) consolidated in the domestic regular session, trading around KRW 178,000 (based on the latest confirmed market price near the KRW 178,000 level).
On the same day, the KOSPI closed at 6,627.26, and the Daily Stock proprietary Fear & Greed Index dropped to "Fear" (25) from "Neutral" (50.9) a week earlier, reflecting entrenched conservative sentiment across risk assets.
The Nasdaq Fear & Greed Index also stood at 30.9 (Fear), while the USD/KRW exchange rate remained elevated at 1,360.10.
Amid this macroeconomic tension, Celltrion stepped up its product differentiation by officially submitting an Investigational New Drug (IND) application for a Phase 4 clinical trial to the U.S. Food and Drug Administration (FDA) on September 15, aiming to secure clinical evidence for a high-dose 240mg administration of Zymfentra.
Unlike its past biosimilar status, Zymfentra—having secured New Drug status in the U.S.—has overcome concerns over formulary listing delays and entered a full-scale prescription volume ramp-up cycle.
| Category | FY2024 | 1H 2025 | 1H 2026 | YoY Change |
|---|---|---|---|---|
| **Zymfentra U.S. Revenue** | KRW 35.7B | KRW 36.0B | KRW 99.5B | +176.4% |
| **Remsima SC Global Revenue** | KRW 312.0B | KRW 296.5B | KRW 356.7B | +20.3% |
| **Combined SC Franchise Revenue** | KRW 347.7B | KRW 332.5B | KRW 456.2B | +37.2% |
| **U.S. PBM Insurance Coverage** | ~40% | ~70% | Over 90% | Accelerated Penetration |
[Image: /stdaily/uploads/202609/gen_6aa8ed2a504ae8.98264101.png]
Financial Analysis
For the second quarter of 2026, Celltrion reported consolidated revenue of KRW 1.3937 trillion and an operating profit of KRW 451.8 billion, setting an all-time quarterly revenue record.
Revenue increased by 45% and operating profit jumped 86.3% year-over-year, while the operating profit margin stood at 32.4%, an improvement of 7.2 percentage points over the same period last year.
The primary driver of this substantial profitability improvement is that high-margin new pipelines—including Zymfentra, Yuflyma, Steqeyma, and Eybenz—expanded their revenue share to 65% of total biopharmaceutical sales.
As the amortization of intangible assets and the depletion of high-cost inventory stemming from the historic Celltrion merger enter their final stages, the cost of goods sold (COGS) ratio declined to 38% in Q2, unlocking significant operating leverage.
With the USD/KRW exchange rate maintaining an elevated level in the 1,360s, Zymfentra—which has a high proportion of U.S. dollar settlements—is enjoying an additional operational margin tailwind in KRW terms.
Valuation
As of the second half of 2026, Celltrion’s 12-month forward price-to-earnings (Forward P/E) multiple stands in the range of approximately 28x to 32x.
This is significantly lower than its historical 5-year average P/E (45x to 55x), indicating that the structural transition from a biosimilar manufacturer to a global pharmaceutical firm with its own direct sales network has not been fully priced in.
Compared to major domestic CMO players such as Samsung Biologics, which trade at P/E multiples of 55x to 65x, Celltrion’s valuation overhang appears relatively moderated.
At a time when major semiconductor and secondary battery stocks within the KOSPI 200 index face price volatility over macroeconomic uncertainty, the scarcity value of a large-cap healthcare company returning to annual operating margins in the 30% range becomes prominent.
However, because actual net sales margins can fluctuate depending on final prescription rebate rates determined under its New Drug pricing status, maintaining conservative earnings estimates remains advisable.
Expert & Institutional Analysis
Major domestic brokerages view the expansion of U.S. Zymfentra prescriptions as the primary medium-to-long-term compass for Celltrion's stock price.
A research center at a major brokerage noted: "Beginning in the second half of 2026, as the full effects of listings across the top three PBM formularies materialize, prescription penetration targeting local U.S. clinics and gastroenterology specialists is expected to sustain a steep monthly growth rate exceeding 20%."
In terms of foreign capital flows, index basket selling triggered by elevated USD/KRW levels in the 1,360s and heightened KOSPI futures volatility continues to exert temporary structural friction.
Conversely, institutional investors interpret the cumulative revenue contributions of the five new products, alongside clinical label expansion strategies in the U.S. (such as the 240mg high-dose regimen), as constructive signals for pipeline depth.
Large pension funds appear to be considering staged dip-buying strategies, pricing in the reduced discount rate on growth biotech stocks as the interest rate cut cycle unfolds.
Risk Factors
The most critical variable to monitor is the uncertainty surrounding rebates and drug-pricing pressure within the U.S. PBM system.
If the administration fees and rebate percentages required to secure preferred formulary status with top-tier PBMs turn out higher than anticipated, the actual bottom-line profit contribution relative to top-line prescription figures could be diminished.
Furthermore, global economic slowdown concerns and government healthcare budget cuts could intensify price-cutting competition in tenders for biosimilars and novel drugs alike.
Foreign exchange risk is also a double-edged sword: a sudden shift toward a weakening dollar (KRW strengthening) could contract foreign earnings when converted into Korean won in the short term.
Lastly, market share competition against rival formulations in the inflammatory bowel disease (IBD) market—such as Takeda’s Entyvio (subcutaneous) and Janssen’s Stelara, as well as oral therapies—requires continued monitoring.
Investment Perspective
Celltrion has largely resolved post-merger integration headwinds, including high COGS ratios and excess inventory burdens, and is demonstrating qualitative growth led by novel therapeutics and next-generation pipelines.
With the KOSPI Fear & Greed Index entering the "Fear" zone at 25, overall market sentiment has driven pullbacks even among blue-chip equities.
The support offered by exchange rates in the 1,360 won range and the prospective monetary policy shift by the Bank of Korea provide a favorable operating backdrop for large-cap biopharma stocks backed by dominant export shares and steady cash flows.
Therefore, rather than reacting to short-term benchmark oscillations, a gradual, dollar-cost averaging approach—cross-verifying quarterly U.S. Zymfentra prescription figures against new European product revenue ramp-ups—presents a balanced strategy.
[Image: /stdaily/uploads/202609/gen_6aa8ed356c83e8.61617891.png]
Q&A with Daily Stock
Q1. What is the fundamental difference between Zymfentra and conventional biosimilars?
Zymfentra is not a simple biosimilar copy; it is an independently improved subcutaneous (SC) formulation of an intravenous (IV) biologic that secured FDA approval as a "New Drug." Consequently, it can command significantly higher pricing than biosimilars and benefit from extended exclusivity backed by patent barriers.
Q2. What is the practical significance of completing listings across the top three U.S. PBMs?
In the U.S. healthcare system, a therapy must be included in the formularies of private Pharmacy Benefit Managers (PBMs) for private health insurance reimbursement to apply. Being listed across all top three PBMs means Celltrion has established the commercial pipeline needed to cover more than 90% of the insured U.S. population.
Q3. How does 1H Zymfentra revenue of KRW 99.5 billion compare with market expectations?
While more modest compared to the aggressive initial guidance (ranging from several hundred billion to 1 trillion won) presented during the initial 2024–2025 launch phase, the therapy has officially entered a steep ramp-up trajectory in 2026, growing 176.4% YoY as covered prescriptions scale.
Q4. What is the purpose of the 240mg Phase 4 clinical trial recently submitted to the FDA?
It is a strategic trial intended to expand dosing options and prevent patient switching to competing therapies by allowing higher-dose regimens for severe autoimmune disease patients who show insufficient response to initial maintenance dosing.
Q5. What is the outlook for Celltrion's supply-demand dynamics amid current KOSPI fear levels?
While foreign institutional selling across benchmark futures and spot baskets may persist due to macro uncertainties indicated by a KOSPI Fear & Greed reading of 25, Celltrion’s confirmed earnings recovery to a 32% operating margin and foreign exchange advantages are likely to provide robust downside support.